Company Overview and News

Westlife Development posts net profit of Rs 11.62 cr in Q1

2018-07-27 moneycontrol
Westlife Development, the master franchisee of McDonald's in west and south India, today posted a net profit of Rs 11.62 crore in the June quarter.

An evening walk down Dalal Street | Sensex, Nifty, Bank indices end at record closing high

2018-07-27 moneycontrol
‘Thank God it’s Friday’ indeed has been the case for D-Street as traders carried on strong momentum all through the week on Friday as well. The Sensex, Nifty and Bank Nifty managed to end the week at record closing highs. In fact, it is the 21st time in 2018 that the index managed to clock this milestone, while the Nifty has achieved it for the 15th time.

Westlife Development surges 19% after posting Q1 profit, double digit growth in same-store-sales growth

2018-07-27 moneycontrol
Westlife Development share price rallied 19 percent intraday Friday after the company posted profit and double digit same-store-sales growth in Q1FY19.

McDonald’s restaurants in India are using cooking oil to power delivery trucks

2018-07-24 cnbc
Ever wondered what happens to the golden oil used to cook your fries and nuggets once it’s no longer needed? Well, in India it’s being used as fuel. The master franchisee for McDonald’s restaurants in west and south India, Hardcastle Restaurants Pvt Ltd (HRPL), is using biodiesel from used cooking oil to power its fleet of delivery trucks in Mumbai. The biodiesel program began as a pilot last year.

McDonald’s recycles used oil to power trucks in sustainability push

2018-07-24 livemint
Mumbai: The oil used to make your French fries are also powering the refrigerated delivery trucks and even the refrigeration equipment aboard the trucks of McDonald’s in Mumbai for the last nine months.

Axis Capital maintains buy on Westlife Development; target Rs 450

2018-06-14 moneycontrol
Shares of Westlife Development advanced 2 percent intraday Thursday as brokerage Axis Capital has maintained buy call on the stock with a target of Rs 450 per share.

New on McDonald’s menu: Patties that don’t have food preservatives

2018-04-03 livemint
Mumbai: Hardcastle Restaurants Pvt. Ltd, the company that runs McDonald’s outlets in south and west India, is now serving food preservative-free patties for Indians who associate preservatives with unhealthy and processed foods.

Hardcastle Restaurants to invest up to Rs 1,000 cr to revamp McDonald#39;s offerings

2018-04-03 moneycontrol
Hardcastle Restaurants, the master franchisee of fast food chain McDonald's in west and south India, plans to invest Rs 800 crore to Rs 1,000 crore over the next three years to introduce healthier food options and digitise its stores.

Westlife Development plans to nearly double count of McDonald#39;s outlets to 500 by 2022

2018-04-03 moneycontrol
Hardcastle Restaurants Pvt Ltd (HRPL), a master franchisee of McDonald’s restaurants in West and South India is planning to take its current 270 outlets to 400-500 outlets by 2022.

McDonald's Has a Legal Problem in Pizza-Loving India - Bloomberg

2018-03-27 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...